Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics

Journal of Theoretical Biology

Volumn 267, Issue 3, 2010, Pages 330-340

  Guedj, J ^a,b   Neumann, A U ^a,c  

^a BAR ILAN UNIVERSITY   (Israel)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c SANTA FE INSTITUTE   (United States)

Author keywords

DAA; HCV; Mathematical modeling; Viral evolution; Viral kinetics

Indexed keywords

ANTIVIRUS AGENT;

CELL ORGANELLE; DRUG RESISTANCE; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; MUTATION; NUMERICAL MODEL; VIRAL DISEASE; VIRUS;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL DIVISION; CELL INTERACTION; CONTROLLED STUDY; GENE SYNTHESIS; HEPATITIS C VIRUS; MATHEMATICAL MODEL; MICROBIAL KINETICS; PREDICTION; PRIORITY JOURNAL; TARGET CELL; VIRION; VIRUS GENOME; VIRUS LOAD; VIRUS RESISTANCE; WILD TYPE;

ALGORITHMS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; KINETICS; MODELS, BIOLOGICAL; VIRAL LOAD; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 77956704553     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.08.036     Document Type: Article

References (45)

1. Adiwijaya B., Hare B., Caron P., Randle J., Neumann A., Reesink H., Zeuzem S., Herrmann E. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 2009, 14(4):591-595.
2. Adiwijaya B., Herrmann E., Hare B., Kieffer T., Lin C., Kwong A., Garg V., Randle J., Sarrazin C., Zeuzem S., Caron P. A multi-variant viral dynamics model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PlOS Comput. Biol. 2010, 6(4):e1000745.
3. Biebricher C., Eigen M., Luce R. Kinetic analysis of template-instructed and de novo RNA synthesis by Q beta replicase. J. Mol. Biol. 1981, 148(4):391-410.
4. Bonhoeffer S., May R., Shaw G., Nowak M. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 1997, 94(13):6971-6976.
5. Bonhoeffer S., Nowak M. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. Roy. Soc. B Biol. Sci. 1997, 264(1382):631-637.
6. Borden E., Sen G., Uze G., Silverman R., Ransohoff R., Foster G., Stark G. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug. Discov. 2007, 6(12):975-990.
7. Dahari H., Ribeiro R., Rice C., Perelson A. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 2007, 81(2):750-760.
8. Dahari H., Sainz B., Perelson A., Uprichard S. Modeling subgenomic HCV RNA kinetics during interferon-a treatment. J. Virol. 2009, 83(13):6383-6393.
9. Egger D., Wolk B., Gosert R., Bianchi L., Blum H., Moradpour D., Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 2002, 76(12):5974-5984.
10. Eigen M., Biebricher C., Gebinoga M., Gardiner W. The hypercycle. Coupling of RNA and protein biosynthesis in the infection cycle of an RNA bacteriophage. Biochemistry 1991, 30(46):11005-11018.
11. Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Goncales F., Haussinger D., Diago M., Carosi G., Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New. Engl. J. Med. 2002, 347(13):975-982.
12. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77(9):5487-5492.
13. Havlir D., Cheeseman S., McLaughlin M., Murphy R., Erice A., Spector S., Greenough T., Sullivan J., Hall D., Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 1995, 171(3):537-545.
14. Herrmann E. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37(6):1351-1358.
15. Kieffer T., Sarrazin C., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Lin C., Purdy S., Weegink C. Wild-type HCV NS3 protease reemerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. J. Hepatol. 2006, 26-30.
16. Krakauer D., Komarova N. Levels of selection in positive-strand virus dynamics. J. Evol. Biol. 2003, 16(1):64.
17. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A., Young S., Lee B., Heckerman D., Carlson J., Reyor L. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008, 48(6):1769.
18. Layden-Almer J., Ribeiro R., Wiley T., Perelson A., Layden T. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37(6):1343-1350.
19. Liu-Young G., Kozal M. Review: Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care and STDs 2008, 22(6):449-457.
20. Marcos A., Fisher R., Ham J., Shiffman M., Sanyal A., Luketic V., Sterling R., Fulcher A., Posner M. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000, 69(7):1375.
21. Maree A., Keulen W., Boucher C., De Boer R. Estimating relative fitness in viral competition experiments. Journal of Virology 2000, 74(11):11067-11072.
22. Neumann A., Lam N., Dahari H., Davidian M., Wiley T., Mika B., Perelson A., Layden T. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 2000, 182(1):28-35.
23. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
24. Nowak M., Bonhoeffer S., Hill A., Boehme R., Thomas H., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 1996, 93(9):4398-4402.
25. Pawlotsky J. Treatment of hepatitis C: don't put all your eggs in one basket!. Gastroenterology 2007, 132(4):1611-1615.
26. Pawlotsky J., Chevaliez S., McHutchison J. The hepatitis c virus life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132(5):1979-1998.
27. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D. Viral dynamics in human immunodeficiency virus type 1 infection. Science 1996, 271:1582-1586.
28. Ramratnam B., Bonhoeffer S., Binley J., Hurley A., Zhang L., Mittler J.E., Markowitz M., Moore J.P., Perelson A.S., Ho D.D. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354:1782-1786.
29. Reesink H., Fanning G., Farha K., Weefink C., VanVliet A., Van'TKlooster G., Lenz O., Aharchi F., Marien K., VanRemoortere P., DeKock H., Broeckaert F., Meyvisch P., VanBeirendonck E., Simmen K., Verloes R. Rapid HCV-RNA decline with once daily TMC435: a phase i study in healthy volunteers and hepatitis C patients. Gastroenterology 2010, 138(3):913-921.
30. Reesink H., Zeuzem S., Weegink C., Forestier N., van Vliet A., van de Wetering de Rooij J., McNair L., Purdy S., Kauffman R., Alam J. Rapid decline of viral RNA in hepatitis C patients treated With VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131(4):997-1002.
31. Richman D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68(3):1660-1666.
32. Roberts S., Cooksley G., Dore G., Robson R., Shaw D., Berns H., Hill G., Klumpp K., Najera I., Washington C. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48(2):398-406.
33. Rodriguez-Inigo E., Lopez-Alcorocho J., Bartolome J., Ortiz-Movilla N., Pardo M., Carreno V. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J. Mol. Diag. 2005, 7(4):535-543.
34. Rong L., Dahari H., Ribeiro R., Perelson A. Rapid emergence of protease inhibitor in hepatitis c virus. Science Transl. Med. 2010, 2(30):30ra32.
35. Saag M., Emini E., Laskin O., Douglas J., Lapidus W., Schleif W., Whitley R., Hildebrand C., Byrnes V., Kappes J., et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New. Engl. J. Med. 1993, 329(15):1065.
36. Sarrazin C., Kieffer T., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Zhou Y., Chu H., Lin C. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132(5):1767-1777.
37. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S., Hussain M., Shah A., Cutler D., Zhang J., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology 2007, 132(4):1270-1278.
38. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 1995, 171(6):1411-1419.
39. Seeff L., Hoofnagle J. Appendix: the national institutes of health consensus development conference management of hepatitis C 2002. Clin. Liver Dis. 2003, 7(1):261-287.
40. Shepard C., Finelli L., Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5(9):558-567.
41. Sherman K., Shire N., Rouster S., Peters M., James Koziel M., Chung R., Horn P. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005, 128(2):313-327.
42. Soriano V., Perelson A., Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. J. Antimicrob. Chemoth. 2008, 62(1):1.
43. Stiffler J., Nguyen M., Sohn J., Liu C., Kaplan D., Seeger C. Focal distribution of hepatitis C virus RNA in infected livers. PlOS one 2009, 4(8):e6661.
44. Tisdale M., Kemp S., Parry N., Larder B. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 1993, 90(12):5653-5656.
45. Wodarz D., Nowak M. Mathematical models of HIV pathogenesis and treatment. BioEssays 2002, 24(12):1178-1187.